Skip to main content

Day: January 7, 2026

Galantas Gold Announces Definitive Agreement to Acquire the Andacollo Oro Gold Project, Chile

Written by Customer Service on . Posted in Mergers And Acquisitions.

TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) — Galantas Gold Corporation (TSX-V: GAL | AIM: GAL) (“Galantas” or the “Company”) is pleased to announce that on January 6, 2026 it has entered into a share purchase agreement (the “Agreement”) to acquire a 100% ownership interest in the Andacollo Oro Gold Project (the “Project”), located in the Coquimbo Region of central Chile (the “Transaction”). The Project is a past-producing, large-scale open pit heap leach gold operation with existing infrastructure, permits, and extensive historical technical data. The acquisition represents a significant strategic step for Galantas and is expected to constitute a Fundamental Acquisition under the policies of the TSX Venture Exchange (“TSXV”). Andacollo Oro Gold Project Overview The Project is located in the Coquimbo Region, Chile, approximately 55...

Continue reading

TTM Technologies, Inc. Announces Upcoming Conference Participation

Written by Customer Service on . Posted in Public Companies.

SANTA ANA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — TTM Technologies, Inc. (NASDAQ: TTMI), today announced that members of its management team will attend the following investor conferences:Edwin Roks, President and Chief Executive Officer, and Dan Boehle, Chief Financial Officer, will participate in the Needham Growth Conference on January 13th and 14th at the Lotte New York Palace Hotel in New York, with a presentation on January 13th at 8:45am Eastern Time.About TTMTTM Technologies, Inc. is a leading global manufacturer of technology products, including mission systems, radio frequency (“RF”) components, RF microwave/microelectronic assemblies, and technologically advanced printed circuit boards (“PCB”s). TTM stands for time-to-market, representing how TTM’s time-critical, one-stop design, engineering and manufacturing...

Continue reading

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Written by Customer Service on . Posted in Public Companies.

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —  HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib, a novel spleen tyrosine kinase (“Syk”) inhibitor, in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China has met its primary endpoint of durable hemoglobin (Hb) response rate within weeks 5 to 24 of treatment. Autoimmune hemolytic anemia (“AIHA”) is an autoimmune disorder characterized by the destruction of red blood cells (“RBCs”) due to the production of antibodies against RBC. The incidence of AIHA is estimated to be 0.8-3.0/100,000 adults per...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.